RNA Clinical Trials Resources

  1. Unmatched Beginnings For Late-Phase Success 6/2/2026

    Early research choices shape outcomes. Focusing on reproducibility, scalability, regulatory fit, and supply stability early cuts risk, prevents delays, and supports smoother development progress.

  2. DPCR, qPCR, And RT-qPCR: Advantages And Challenges In Development 5/27/2026

    Discover how the right PCR strategy, combined with thoughtful assay design and validation, can strengthen confidence in your molecular research and clinical testing workflows.

  3. Price Matters - Why Dash Believes In Transparency 5/15/2026

    Opaque pricing slows decisions and erodes trust. Transparency clarifies cost drivers, improves budgeting, enables confident sourcing, and strengthens long-term R&D partnerships.

  4. The Bioanalysis CRO Selection Checklist Every Sponsor Should Use Before Signing An MSA 3/9/2026

    Choosing a CRO requires more than proposals. Assess reliability, automation, GLP rigor, scientific engagement, pricing clarity, and capacity to find partners who deliver defensible data on real timelines.

  5. GLP Compliance In A Modern Lab: What Compliant Actually Requires In 2025 3/9/2026

    GLP compliance isn’t binary. Real defensibility depends on rigorous QA, validated electronic systems, and operational maturity — not just a label.

  6. What Sponsors Get Wrong When Selecting A CRO 3/9/2026

    Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

  7. Why CGT Programs Need A Different CRO Mindset 3/9/2026

    Advanced therapies need bioanalysis partners built for complexity, not scale. CGT expertise, specialized platforms, and flexible timelines ensure dosing and safety data traditional CROs can’t support.

  8. Transparent Pricing In Bioanalysis: A Feature, Not A Bonus 3/9/2026

    Unclear CRO pricing leaves small biotechs vulnerable to budget swings. Transparent, itemized costs cut financial risk, sharpen planning, and build trust by setting expectations from the start.

  9. How Smaller Biotechs Are Rethinking CRO Relationships Post-Pandemic 3/9/2026

    Smaller biotechs are rethinking CRO partnerships, valuing speed, scientific access, flexibility, and transparent pricing over scale — driven by pandemic lessons and a sharper focus on operational fit.

  10. The Bioanalysis Report You Actually Get Back Fast 3/9/2026

    Manual bioanalysis variability creates data noise. Automation replaces inconsistencies with repeatable processes that boost precision, support compliance, and deliver more reliable results.